search
Back to results

rTMS in Treatment Refractory Obsessive-Compulsive Disorder

Primary Purpose

Obsessive-Compulsive Disorder

Status
Withdrawn
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
rTMS
Sponsored by
McMaster University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obsessive-Compulsive Disorder focused on measuring rTMS, treatment refractory, treatment resistant, SSRI, clomipramine

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with a primary diagnosis of OCD (DSM 5) according to the MINI
  • Y-BOCS score of ≥20
  • History of treatment-resistant OCD, established by a trained psychiatrist with extensive expertise in the OCD field. Treatment-resistance will be defined as non-response to at least two SRIs trials (clomipramine, fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, escitalopram).

Exclusion Criteria:

  • Any additional current psychiatric comorbidity, except for mild depressive and anxious symptoms
  • A lifetime DSM-5 diagnosis of schizophrenia or other psychotic syndromes, substance dependence or substance abuse, including alcohol, bipolar I or II disorder, mental disorder due to a general medical condition
  • Serious suicide risk
  • Episodic OCD
  • Illness duration less than two years
  • Hospitalization in the last 6 months
  • Pharmacological treatment changes in the last 3 months
  • The inability to receive rTMS because of metallic implants, or history of seizures (personal or family history of seizure in first degree relatives)
  • Any major medical disease
  • Pregnancy or nursing of an infant
  • The inability or refusal to provide informed consent
  • Prior TMS exposure (in order to reduce the risk of unblinding).

No psychotherapy and/or pharmacological treatment changes will be allowed during the study period. Pharmacologically treated patients should be on constant medications for at least 2 weeks before entering the study.

Sites / Locations

  • MacAnxiety Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Active rTMS

Sham rTMS

Arm Description

In rTMS, a device called a "stimulator" provides energy to a "magnetic coil". The coil is a handheld unit that delivers magnetic pulses. The coil is placed against the scalp on the top of your head. Sessions will occur once a day, 5 days/week, for 3 weeks.

The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.

Outcomes

Primary Outcome Measures

Yale Brown Obsessive Compulsive Scale

Secondary Outcome Measures

Barratt Impulsiveness Scale
Hamilton Anxiety rating Scale
Hamilton Depression Rating Scale
Clinical Global Impression Scale

Full Information

First Posted
May 19, 2015
Last Updated
June 14, 2019
Sponsor
McMaster University
Collaborators
St. Joseph's Healthcare Hamilton, Hamilton Health Sciences Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT02450695
Brief Title
rTMS in Treatment Refractory Obsessive-Compulsive Disorder
Official Title
A Randomized Crossed-over Trial Examining Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment Refractory Obsessive-Compulsive Disorder.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2019
Overall Recruitment Status
Withdrawn
Why Stopped
No participants were recruited.
Study Start Date
July 2016 (undefined)
Primary Completion Date
April 2019 (Anticipated)
Study Completion Date
April 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
McMaster University
Collaborators
St. Joseph's Healthcare Hamilton, Hamilton Health Sciences Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will evaluate the effectiveness of rTMS as a potential treatment for refractory OCD in a randomized, crossover design.
Detailed Description
The study is a minimum of 7 weeks long. In the first treatment phase (three weeks), participants will be randomly assigned to one of two treatment conditions: active rTMS or sham rTMS. The "sham" rTMS is the inactive form of the treatment where the experience during the sessions will be similar to an active rTMS session, but it will have no medical value. During these 3 weeks, they will attend a session each day for 5 days per week at Mood Disorders Clinic located at St. Joseph's Healthcare. Each of these sessions will be an hour long totalling 15 visits in the first 3 weeks. After every 5 sessions they will be asked to complete the following self-report questionnaires: Baratt Impulsiveness Scale, Hamilton Anxiety Rating Scale and the Hamilton Depression Rating Scale. The clinician-rated: Clinical Global Impression Scale and Yale Brown Obsessive Compulsive Scales will also be completed. The two treatment phases will be separated by a flexible wash-out of a minimum of one week where participants will not attend any visits. After this, they will begin the second treatment phase (three weeks) which will be the treatment condition they were not previously assigned to. In other words, individuals previously on the active rTMS treatment will now begin sham rTMS treatment and vice versa. These sessions will be identical to those involved in the first treatment phase, except the treatment condition will be different. Before and after each treatment session they will also be asked a series of questions to rate potential rTMS side effects and complete a cognitive task known as the "Go/no-go task."

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obsessive-Compulsive Disorder
Keywords
rTMS, treatment refractory, treatment resistant, SSRI, clomipramine

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active rTMS
Arm Type
Experimental
Arm Description
In rTMS, a device called a "stimulator" provides energy to a "magnetic coil". The coil is a handheld unit that delivers magnetic pulses. The coil is placed against the scalp on the top of your head. Sessions will occur once a day, 5 days/week, for 3 weeks.
Arm Title
Sham rTMS
Arm Type
Sham Comparator
Arm Description
The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.
Intervention Type
Device
Intervention Name(s)
rTMS
Primary Outcome Measure Information:
Title
Yale Brown Obsessive Compulsive Scale
Time Frame
7 Weeks
Secondary Outcome Measure Information:
Title
Barratt Impulsiveness Scale
Time Frame
7 Weeks
Title
Hamilton Anxiety rating Scale
Time Frame
7 weeks
Title
Hamilton Depression Rating Scale
Time Frame
7 Weeks
Title
Clinical Global Impression Scale
Time Frame
7 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a primary diagnosis of OCD (DSM 5) according to the MINI Y-BOCS score of ≥20 History of treatment-resistant OCD, established by a trained psychiatrist with extensive expertise in the OCD field. Treatment-resistance will be defined as non-response to at least two SRIs trials (clomipramine, fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, escitalopram). Exclusion Criteria: Any additional current psychiatric comorbidity, except for mild depressive and anxious symptoms A lifetime DSM-5 diagnosis of schizophrenia or other psychotic syndromes, substance dependence or substance abuse, including alcohol, bipolar I or II disorder, mental disorder due to a general medical condition Serious suicide risk Episodic OCD Illness duration less than two years Hospitalization in the last 6 months Pharmacological treatment changes in the last 3 months The inability to receive rTMS because of metallic implants, or history of seizures (personal or family history of seizure in first degree relatives) Any major medical disease Pregnancy or nursing of an infant The inability or refusal to provide informed consent Prior TMS exposure (in order to reduce the risk of unblinding). No psychotherapy and/or pharmacological treatment changes will be allowed during the study period. Pharmacologically treated patients should be on constant medications for at least 2 weeks before entering the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Van Ameringen, MD, FRCPC
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
MacAnxiety Research Center
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8S 1B7
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

rTMS in Treatment Refractory Obsessive-Compulsive Disorder

We'll reach out to this number within 24 hrs